ArticleJournal of experimental & clinical cancer research : CR2010
Co-expression and impact of prostate specific membrane antigen and prostate specific antigen in prostatic pathologies.
Article in Journal of experimental & clinical cancer research : CR, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 44 citations in OpenAlex.
- Clinical Relevance of Prostate-Specific Membrane Antigen-Lipid Rafts Association and Membrane Protein Interactions in Prostatic Adenocarcinoma.World journal of oncology · 2026Article
- The Transcriptomic Profiles ofInternational journal of molecular sciences · 2023Article
- Rapamycin and Low-dose IL-2 Mediate an Immunosuppressive Microenvironment to Inhibit Benign Prostatic Hyperplasia.International journal of biological sciences · 2023Article
- Characterization of the Tumor Microenvironment and the Biological Processes with a Role in Prostatic Tumorigenesis.Biomedicines · 2022Article
- KLK3 in the Regulation of Angiogenesis-Tumorigenic or Not?International journal of molecular sciences · 2021Review
- Molecular Imaging in Primary Staging of Prostate Cancer Patients: Current Aspects and Future Trends.Cancers · 2021Review
- Mucin-1 expression and localization in epithelial cells shows characteristic and distinct patterns in inflammatory bowel diseases and colorectal cancer.International journal of clinical and experimental pathology · 2019Article
- Expression of Prostate-Specific Membrane Antigen (PSMA) on Biopsies Is an Independent Risk Stratifier of Prostate Cancer Patients at Time of Initial Diagnosis.Frontiers in oncology · 2018Article
- Specific Delivery of MiRNA for High Efficient Inhibition of Prostate Cancer by RNA Nanotechnology.Molecular therapy : the journal of the American Society of Gene Therapy · 2016Article
- Prostate-specific membrane antigen targeted protein contrast agents for molecular imaging of prostate cancer by MRI.Nanoscale · 2016Article
- Article
- SULF2 overexpression positively regulates tumorigenicity of human prostate cancer cells.Journal of experimental & clinical cancer research : CR · 2015Article
- Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I/IIa study.Journal for immunotherapy of cancer · 2015Article
- KLK-targeted Therapies for Prostate Cancer.EJIFCC · 2014Article
- Clinical significance of NUCB2 mRNA expression in prostate cancer.Journal of experimental & clinical cancer research : CR · 2013Article
- The proinflammatory cytokine, IL-6, and its interference with bFGF signaling and PSMA in prostate cancer cells.Inflammation · 2013Article
- A comparison of the biological features of prostate cancer with (PSA+, PSMA+) profile according to RKIP.BioMed research international · 2013Article
- DNA Vaccines for Prostate Cancer.Current cancer therapy reviews · 2012Article
- NF-κB signaling in prostate cancer: a promising therapeutic target?World journal of urology · 2012Review
- Development of a Single Stranded DNA Aptamer as a Molecular Probe for LNCap Cells Using Cell-SELEX.Avicenna journal of medical biotechnologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study was undertaken to relate the co-expression of prostate-associated antigens, PSMA and PSA, with the degree of vascularization in normal and pathologic (hyperplasia and cancer) prostate tissues to elucidate their possible role in tumor progression.
methodsThe study was carried out in 6 normal, 44 benign prostatic hyperplastic and 39 cancerous human prostates. Immunohistochemical analysis were performed using the monoclonal antibody CD34 to determine the angiogenic activity, and the monoclonal antibodies 3E6 and ER-PR8 to assess PSMA and PSA expression, respectively.
resultsIn our study we found that in normal prostate tissue, PSMA and PSA were equally expressed (3.7 ± 0.18 and 3.07 ± 0.11). A significant difference in their expression was see in hyperplastic and neoplastic prostates tissues (16.14 ± 0.17 and 30.72 ± 0.85, respectively) for PSMA and (34.39 ± 0.53 and 17.85 ± 1.21, respectively) for PSA. Study of prostate tumor profiles showed that the profile (PSA+, PSMA-) expression levels decreased between normal prostate, benign prostatic tissue and primary prostate cancer. In the other hand, the profile (PSA-, PSMA+) expression levels increased from normal to prostate tumor tissues. PSMA overexpression was associated with high intratumoral angiogenesis activity. By contrast, high PSA expression was associated with low angiogenesis activity.
conclusionThese data suggest that these markers are regulated differentially and the difference in their expression showed a correlation with malignant transformation. With regard to the duality PSMA-PSA, this implies the significance of their investigation together in normal and pathologic prostate tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.